NCT04644809View on ClinicalTrials.gov

A Study of LY3561774 in Participants With Dyslipidemia

PHASE1CompletedINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

November 30, 2020

Primary Completion Date

May 17, 2022

Study Completion Date

May 17, 2022

Conditions
Dyslipidemias
Interventions
DRUG

LY3561774

Administered SC.

DRUG

Placebo

Administered SC.

Trial Locations (5)

33143

Qps-Mra, Llc, South Miami

37920

Alliance for Multispecialty Research, LLC, Knoxville

90630

Altasciences Clinical Los Angeles, Inc, Cypress

90806

Collaborative Neuroscience Research, LLC, Long Beach

08053

Hassman Research Institute, Marlton

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT04644809 - A Study of LY3561774 in Participants With Dyslipidemia | Biotech Hunter | Biotech Hunter